Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sebetralstat (Primary)
  • Indications Hereditary angioedema
  • Focus Registrational; Therapeutic Use
  • Acronyms KONFIDENT
  • Sponsors KalVista Pharmaceuticals

    • Most Recent Events

    • 07 Oct 2024 According to a KalVista Pharmaceuticals media release, the company presented data showing the effectiveness of sebetralstat in reducing anxiety among people experiencing hereditary angioedema (HAE) attacks at the HAEi Global Angioedema Forum (GAF) taking place in Copenhagen, Denmark, October 4 - 5, 2024.
    • 30 Sep 2024 According to a KalVista Pharmaceuticals media release, company announced Marketing Authorization Application (MAA) submissions to the regulatory authorities in the United Kingdom Switzerland, Australia, and Singapore for sebetralstat, for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older based on the results of KONFIDENT and e KONFIDENT-S.
    • 26 Sep 2024 According to a KalVista Pharmaceuticals media release, results form this trial will be presented at the HAEi Global Angioedema Forum (GAF) taking place in Copenhagen, Denmark October 4-5, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top